Caring Brands Inc

This proposal asks stockholders to approve the Additional Investment Right contained in Section 4.19 of the SPA, which would permit each Purchaser to purchase additional Series A Convertible Preferred Stock and Warrants on the same terms as the initial closing for up to eighteen months after the closing date. Management seeks shareholder approval primarily to comply with Nasdaq Listing Rule 5635(d), which requires shareholder approval for transactions that could result in issuance of 20% or more of outstanding common shares at a price below the applicable Minimum Price. Approval would preserve the Company’s Nasdaq compliance while enabling the Purchasers to invest additional capital under the same terms, giving the Company potential additional financing flexibility. The proxy discloses the potential adverse effects, including dilution to existing holders and possible downward pressure on market price if shares are sold into the public market. The Series A Preferred Stock and Warrants are convertible/exercisable into common shares; conversion/exercise could exceed the 19.99% threshold absent shareholder approval, which triggers Nasdaq approval requirements. Management’s recommendation is unanimously “FOR,” emphasizing the procedural and marketplace necessity rather than a change to governance rights. There is no indication that directors or officers have any special interest beyond that of other stockholders. From a governance perspective, the vote primarily balances Nasdaq compliance and the company’s near-term financing needs against dilution risk; analysts should weigh the likelihood of Purchasers exercising the Additional Investment Right within 18 months and the conversion/exercise pricing relative to market to assess dilution and price impact. Given the narrow regulatory compliance rationale and the financing flexibility it preserves, the proposal is predictable and routine for companies relying on investor backstops, but it bears monitoring for actual future issuance levels and any below-market conversion or exercise pricing that could materially impact minority holders.

This proposal seeks shareholder authorization for issuance of common stock that may be issued upon conversion of the Series A Convertible Preferred Stock and exercise of the Warrants sold under the SPA, including any issuance exceeding 19.99% of the Company’s outstanding common stock as of the SPA date. Management is pursuing this vote to satisfy Nasdaq Rule 5635(d), which requires shareholder approval when a non-public financing could result in issuance of 20% or more of outstanding shares at potentially below-market prices; without approval the issuances could violate listing rules. The SPA contemplates up to $3.6 million of Series A Preferred and warrants with a $0.40 exercise price and five-year term; the Certificate of Designation limits conversions above 19.99% until shareholder approval is obtained, so this vote would lift that limitation. The company discloses standard anti-dilution and conversion adjustment provisions and warns of dilution and possible adverse pressure on market price if conversion/exercise shares enter the market. The Board unanimously recommends a “FOR” vote, framing the matter as necessary corporate housekeeping to permit the SPA transactions to close and to preserve Nasdaq listing. Notably, holders of Series A purchased in the offering are not entitled to vote those Series A shares on this proposal, which may shape the voting calculus depending on ownership distribution. For investors and analysts, the key evaluation points are the conversion/exercise economics relative to current market price, the potential magnitude of dilution if full conversion/exercise occurs, and the strategic use of proceeds; these factors determine whether the financing materially benefits the company’s operations or principally dilutes existing holders. Given the explicit Nasdaq compliance motive and financing terms already negotiated, the proposal is transactional and regulatory in nature, but with tangible economic consequences depending on how many underlying shares are ultimately issued.

This proposal requests shareholder approval to amend the Company’s Articles of Incorporation to increase authorized common shares from 100 million to 500 million, expanding the pool of shares available for issuance for corporate purposes. Management and the Board argue the increase is needed to preserve flexibility for capital-raising transactions, strategic acquisitions, and employee and director equity compensation programs without the delay and cost of further shareholder votes, and they state no immediate arrangements exist to use the shares other than the SPA-related transactions. Adoption alone does not dilute existing holders, but any future issuances would dilute ownership and potentially voting power if not done pro rata. The Board asserts the increase is not intended as an anti-takeover device and is not proposed in response to any pending acquisition attempt, although increases in authorized shares can, in theory, be used defensively. The Board unanimously recommends a “FOR” vote, emphasizing corporate flexibility and administrative efficiency as the rationale. Analysts should consider the company’s near-term capital needs and the SPA’s conversion/exercise exposure when assessing the practical implications of this increase, as the authorized share ceiling may enable larger issuances tied to financing. Governance-focused investors may request additional assurances or limitations (e.g., shareholder preemptive rights or issuance governance) to limit potential dilution; absent such protections, the authorization broadens management’s discretion. Overall, this is a standard corporate housekeeping measure to ensure adequate authorized capital, but one with meaningful dilution risk if the Board elects to issue a significant portion of the newly authorized shares.

This procedural proposal asks shareholders to authorize the meeting chair and Board to adjourn the Special Meeting one or more times to solicit additional proxies if there are not sufficient votes to approve the SPA-related proposals and the authorized share increase. Management seeks this authority to preserve the option to continue solicitation rather than allow the proposals to fail for lack of votes at the scheduled meeting; this is a common mechanism in proxy practice to ensure critical corporate transactions can be completed after additional outreach. If approved, previously submitted proxies can be revoked before exercise at the adjourned meeting, and the Company may continue to solicit favorable votes; if not approved and the primary proposals lack votes, the Company could be forced to abandon or delay the transactions. The Board recommends a “FOR” vote, presenting the measure as necessary contingency planning to implement the financing and corporate authorization items. From a governance perspective, the adjournment authority concentrates flexibility in management to extend the solicitation period and may be used to target holders who have not yet voted; shareholders should consider whether management has adequate reasons to extend solicitation based on expected vote shortfalls. The practical importance of this proposal depends on the distribution of voting power among holders and whether the SPA-related purchasers can or will vote remaining eligible shares in favor; note that Series A shares purchased in the offering may be restricted from voting on certain proposals. Analysts should monitor voting results and subsequent solicitation activity if the adjournment authority is used, since it signals management’s intent to pursue approval even if initial support is incomplete. Overall, the adjournment proposal is routine but can materially affect the timing and outcome of the substantive approvals being sought.